Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
Would you consider leaving fever untreated in patients with sepsis to potentially enhance immune responses and antimicrobial efficacy?
Tilanus A, et al., PMID 41113323
Related Questions
Do you recommend treatment of male partners for patients with recurrent bacterial vaginosis?
Do you treat with antibiotics active against methicillin-resistant staphylococci when a patient's culture grows non-lugdunensis, coagulase-negative staphylococci that tests susceptible to oxacillin by phenotypic testing, given the low constitutive PbP2A production of most CoNS?
What factors do you consider when deciding between monotherapy with an antipseudomonal cephalosporin and combination therapy in ICU patients with Pseudomonas aeruginosa bloodstream infection who are not in septic shock?
With OpenBiome no longer in operation, what is your current approach for obtaining FMT for inpatients with acute severe/fulminant C. difficile infection unresponsive to antibiotics?
For a patient on appropriate treatment for invasive aspergillosis, how do you determine if and when it is acceptable to reintroduce a TNF inhibitor that likely contributed to their acquisition of the infection but is considered essential for control of their inflammatory condition?
Do routinely recommend antifungal prophylaxis for non-transplant patients who have been diagnosed and completed treatment for possible/probable pulmonary aspergillosis and who will need varying degrees of ongoing immunosuppression?
How do you utilize (1,3)-beta-D-glucan in CSF for diagnosing and monitoring non-cryptococcal CNS fungal infections?
What is the best way to manage close contacts of patients with invasive group A streptococcal infections to minimize the risk of disease transmission while considering the potential adverse effects of prophylactic antibiotics?
Do you recommend chronic oral suppressive antibiotics after initial intensive treatment of 6-8 weeks in patients with culture-negative prosthetic joint or bone infections with retained hardware?
How do you approach perioperative antimicrobial prophylaxis in patients undergoing reconstructive surgery with myocutaneous flaps whom have recently been treated for active infection?
